

NUC-3373 induces endoplasmic reticulum stress in colorectal cancer cells





Fiona G. McKissock, Asmithaa Prabhakaran, Peter Mullen, David J. Harrison - School of Medicine, University of St Andrews, United Kingdom

Background

- 5-fluorouracil (5-FU) is a key anti-cancer drug used across a broad range of tumors
- Fluorodeoxyuridine-monophosphate (FUDR-MP), the anti-cancer metabolite of 5-FU, causes cell death by:
 - Inhibiting thymidylate synthase (TS)
 - Reducing the pool of deoxythymidine monophosphate (dTMP)
- Poor response to 5-FU is a consequence of:
 - Over 85% of 5-FU broken down by dihydropyrimidine dehydrogenase (DPD)¹
 - Limited dosing due to side effects caused by the accumulation of toxic metabolites²
- Key cancer resistance mechanisms:
 - Cellular uptake dependent on nucleoside transporters³
 - Complex enzymatic activation to yield active anti-cancer metabolite FUDR-MP³
- Short plasma half-life (8-14 minutes) results in prolonged administration times (>46hours)

NUC-3373 bypasses the key cancer resistance pathways of 5-FU



NUC-3373: A targeted inhibitor of TS

- ProTide transformation of 5-FU
- Designed to overcome the key 5-FU resistance mechanisms^{4,5}
 - Protected from breakdown by DPD
 - Cellular uptake independent of nucleoside transporters
 - FUDR-MP generation independent of intracellular enzymatic activation
- 366x higher intracellular levels of FUDR-MP than 5-FU *in vitro*⁶
- Significantly greater anti-cancer activity *in vivo* compared to 5-FU
- Favorable toxicology profile compared to 5-FU

Methods

- Nine colorectal cancer (CRC) cell lines investigated
- IC₅₀ values determined by sulforhodamine B assay
- Two cell lines selected for further characterization based on their sensitivity to NUC-3373
 - HCT116 (sensitive)
 - SW480 (less sensitive)
- BiP protein expression measured by Western blot (whole cell lysates)
- CHOP gene expression assessed by RT-qPCR
- Ultrastructural changes assessed by TEM in sections from glutaraldehyde fixed cells

Unbiased stereology was used to determine changes in ER structure




Figure 1. TEM sample preparation and micrograph acquisition

- The volume density (Vv) refers to the volume of the organelle within the reference space, *i.e.* the volume of ER in the volume of cytoplasm
 $Vv(ER, Cyt) = \frac{\sum \text{points on ER}}{\sum \text{points on cytoplasm}}$
- The surface density (Sv) refers to the surface area of ER membrane within the reference space, *i.e.* the surface area of ER in the volume of cytoplasm
 $Sv(ER, Cyt) = \frac{\sum \text{line intersects with ER}}{\sum \text{points on cytoplasm}}$

Results

NUC-3373 activates the unfolded protein response




Figure 2. Representative Western blots and quantification of BiP protein expression in HCT116 and SW480 cells

- NUC-3373 induces BiP expression, indicating that the unfolded protein response is activated

NUC-3373 induces prolonged and unmitigated ER stress




Figure 3. Fold-change in CHOP gene expression in response to NUC-3373 treatment

- NUC-3373 upregulates CHOP gene expression in HCT116 cells, indicating prolonged and unmitigated ER stress
- In contrast to HCT116 cells, NUC-3373 has a less pronounced effect on CHOP in SW480 cells




Figure 4. The unfolded protein response: survival vs. apoptosis

NUC-3373 induces ultrastructural changes in ER




Figure 5. Representative TEM micrographs of cells before and after treatment with 10 μM NUC-3373 (scale bar = 1 μm) white triangles pointing to ER



Figure 6. Quantification of ultrastructural changes to ER in response to 10 μM NUC-3373




Figure 7. NUC-3373 induces differential stress response mechanisms in HCT116 and SW480 cell lines

Conclusion

- In addition to being a potent inhibitor of TS, NUC-3373 can also induce cancer cell death by triggering the ER stress response
- Differential ER stress responses were observed in HCT116 and SW480 CRC cell lines
- The on-going NuTide:302 clinical study is investigating NUC-3373 in combination with other anti-cancer agents